About: Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions
Creator	Alwafi, Hassan Naser, Abdallah Shabrawishi, Mohammed Aldobyany, Ahmad Touman, Abdelfattah
Source	MedRxiv
abstract	BACKGROUND: Despite lack of convincing evidence of the efficacy of hydroxychloroquine, it has been suggested to be used for the treatment of SARS CoV 2 to accelerate the negative virus conversion. We aimed to explore the association between negative nasopharyngeal SARS CoV 2 PCR clearance and different therapeutic interventions. METHODOLOGY: This was a retrospective cohort study of 93 patients who were admitted to medical ward with a PCR confirmed diagnosis of COVID 19 and met the inclusion criteria in a tertiary hospital in Mecca, Saudi Arabia. There were three interventional subgroups (group A (n=45): who received antimalarial drug only classified as (A1), combined with azithromycin (A2) or combined with antiviral drugs (A3)), and one supportive care group (group B) (n=48). The primary and secondary endpoints of the study were achieving negative SARS_CoV_2 nasopharyngeal PCR sample within five days or less from the start of the intervention and 12 days or less from the diagnose, respectively. RESULTS: The mean age of the patients was 43.9 years (SD:15.9). A median time of 3.00 days (IQR:2.00 to 6.50) needed from the time of starting the intervention/supportive care to the first negative PCR sample. There was no statistically significant difference neither between the percentage of patients in the interventional group and the supportive care group who achieved the primary or the secondary endpoint, nor in the median time needed to achieve the first negative PCR sample (p>0.05). CONCLUSION: Prescribing antimalarial medications was not shown to shorten the disease course nor to accelerate the negative PCR conversion rate.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1101/2020.05.08.20095679
has license	medrxiv
sha1sum (hex)	9b8e57f6172111433ac7c7772f58aab953f4f199
schema:url	https://doi.org/10.1101/2020.05.08.20095679
resource representing a document's title	Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions
resource representing a document's body	covid:9b8e57f6172111433ac7c7772f58aab953f4f199#body_text
is schema:about of	named entity 'conversion' named entity 'PCR' named entity 'PCR' named entity 'Authors' named entity 'THERAPEUTIC INTERVENTIONS' named entity 'suggested' named entity 'therapeutic' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'PCR' named entity '5.00' named entity 'preprint' named entity 'nasopharyngeal' named entity 'PCR' named entity 'COVID' named entity 'PCR' named entity 'preprint' named entity 'HCQ' named entity 'PCR' named entity 'supportive care' named entity 'KSA' named entity 'chloroquine' named entity 'SARS-COV-2' named entity 'antimalarial drug' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'preprint' named entity 'HCQ' named entity 'pneumonia' named entity 'non-normally distributed' named entity 'PCR' named entity 'COVID' named entity 'ICU' named entity 'supportive care' named entity 'PCR' named entity 'preprint' named entity 'azithromycin' named entity 'monotherapy' named entity 'ritonavir' named entity 'virus' named entity 'control group' named entity 'PCR' named entity 'SARS-CoV-2' named entity 'chloroquine' named entity 'demographic characteristics' named entity 'COVID' named entity 'preprint' named entity 'clinical trial' named entity 'medRxiv' named entity 'dry cough' named entity 'supportive care' named entity 'dry cough' named entity 'preprint' named entity 'combination therapy' named entity 'supportive care' named entity 'ventricular arrhythmias' named entity 'asymptomatic carriers' named entity 'oxygen supplementation' named entity 'PCR' named entity 'infectious disease' named entity 'treatment groups' named entity 'ritonavir' named entity 'antiviral medications' named entity 'preprint' named entity 'peer review' named entity 'chloroquine' named entity 'antiviral' named entity 'lung' named entity 'statistical significance' named entity 'PCR' named entity 'PCR' named entity 'pharmacological' named entity 'Touman' named entity 'demographic groups' named entity 'respiratory failure' named entity 'azithromycin' named entity 'Kruskal-Wallis test' named entity 'Touman' named entity 'life-threatening' named entity 'supportive care' named entity 'histogram'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software